Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CNS Pharmaceuticals, Inc.CNSP · Entity 8048 | Director | November 17, 2025 | November 20, 2025 |
| Quantum-Si IncQSI · Entity 6440 | Chief Financial Officer | September 21, 2026 | September 23, 2026 |
| STAR EQUITY HOLDINGS, INC.DRAD · Entity 76212 | Chief Financial Officer | February 28, 2018 | March 01, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CNS Pharmaceuticals, Inc.
Report date November 17, 2025 · Filed November 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $12.48 · Expires 2035-11-17 | Direct | 1,517 |
Reported balance
After 2025-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-17 · Grant · Acquired 1,517 · Balance 1,517 F1: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date"). F3: Issued in connection with the reporting person's employment with the Company. F2: The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date").
F2: The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date.
F3: Issued in connection with the reporting person's employment with the Company.
Quantum-Si Inc
Report date September 21, 2026 · Filed September 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,716,684 |
Ending reported balance
After 2026-09-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-21 · Sale · Disposed 5,172 · Balance 1,719,177 F1: Represents shares sold pursuant to a mandatory Quantum-Si sell-to-cover provision for required federal, state and local withholding taxes in connection with the vesting of previously granted restricted stock units. Individual is not able to alter this mandatory sell-to-cover provision that is enacted at the grant date of the related restricted stock unit award. F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $0.75 to $0.762 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 2 · 2026-09-22 · Sale · Disposed 2,493 · Balance 1,716,684 F1: Represents shares sold pursuant to a mandatory Quantum-Si sell-to-cover provision for required federal, state and local withholding taxes in connection with the vesting of previously granted restricted stock units. Individual is not able to alter this mandatory sell-to-cover provision that is enacted at the grant date of the related restricted stock unit award. F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $0.7511 to $0.7779 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold pursuant to a mandatory Quantum-Si sell-to-cover provision for required federal, state and local withholding taxes in connection with the vesting of previously granted restricted stock units. Individual is not able to alter this mandatory sell-to-cover provision that is enacted at the grant date of the related restricted stock unit award.
F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $0.75 to $0.762 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $0.7511 to $0.7779 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
STAR EQUITY HOLDINGS, INC.
Report date February 28, 2018 · Filed March 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,696 |
Reported balance
After 2018-02-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-02-28 · Exercise / conversion · Acquired 6,617 · Balance 49,696 F1: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 46,990 |
Reported balance
After 2018-02-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2018-02-28 · Tax withholding · Disposed 2,706 · Balance 46,990 F3: Shares withheld by Registrant to satisfy the minimum statutory tax withholding requirements on vesting of Restricted Stock Units. No shares were sold. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 19,852 |
Reported balance
After 2018-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-28 · Exercise / conversion · Disposed 6,617 · Balance 19,852 F1: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date. F4: On February 28, 2017, Mr. Keyes was granted 52,937 Restricted Stock Units. As to this grant, 25% of the Restricted Stock Units vest on each of February 28, 2018, February 1, 2019, February 1, 2020 and February 1, 2021, with vesting of 50% of each such Restricted Stock Unit tranche subject to the satisfaction of certain performance criteria to be determined and approved by the Compensation Committee with respect to each such period. F6: Does not include Restricted Stock Units that did not vest and were cancelled. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 33,493 |
Reported balance
After 2018-02-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-28 · Grant · Acquired 33,493 · Balance 33,493 F1: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F5: These Restricted Stock Units are scheduled to vest as to 25% of the units on each of February 28, 2019, February 28, 2020, February 28, 2021 and February 28, 2022, subject to the reporting person continuing to provide service through each such date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 33,493 |
Reported balance
After 2018-02-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-02-28 · Grant · Acquired 33,493 · Balance 33,493 F1: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F7: These Restricted Stock Units are scheduled to vest as to 25% of the units on each of February 28, 2019, February 28, 2020, February 28, 2021 and February 28, 2022, with the vesting of 100% of each such tranche subject to the satisfaction of certain performance criteria to be determined and approved by the Compensation Committee with respect to each such period. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.
F2: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date.
F3: Shares withheld by Registrant to satisfy the minimum statutory tax withholding requirements on vesting of Restricted Stock Units. No shares were sold.
F4: On February 28, 2017, Mr. Keyes was granted 52,937 Restricted Stock Units. As to this grant, 25% of the Restricted Stock Units vest on each of February 28, 2018, February 1, 2019, February 1, 2020 and February 1, 2021, with vesting of 50% of each such Restricted Stock Unit tranche subject to the satisfaction of certain performance criteria to be determined and approved by the Compensation Committee with respect to each such period.
F5: These Restricted Stock Units are scheduled to vest as to 25% of the units on each of February 28, 2019, February 28, 2020, February 28, 2021 and February 28, 2022, subject to the reporting person continuing to provide service through each such date.
F6: Does not include Restricted Stock Units that did not vest and were cancelled.
F7: These Restricted Stock Units are scheduled to vest as to 25% of the units on each of February 28, 2019, February 28, 2020, February 28, 2021 and February 28, 2022, with the vesting of 100% of each such tranche subject to the satisfaction of certain performance criteria to be determined and approved by the Compensation Committee with respect to each such period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2016 Filed Nov 4, 2016 16:28 UTC | STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 | PurchaseCommon Stock | 1,500 | $4.23 | $6,349.95 |
DisclosureSEC source: 0000921895-16-006003 · form409271004_11042016.xml · nonDerivative · entry 1 Keyes Jeffry R. · CIK 0001557736 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,215 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.25, inclusive. Mr. Keyes undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.